$MORF Reports Positive Interim Results from Phase 1Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057 1. MORF-057 well tolerated in all dose cohorts. 2. MORF-057 achieved greater than 95% mean receptor occupancy of integrin at three highest dose levels; demonstrates ability to saturate receptor 3. Data provide early clinical proof of concept for MORF-057 as an oral, selective inhibitor. 4. Phase 1 multiple ascending dose and food effect trials ongoing “We’re excited to present the totality of the Phase 1 trial data later this year and to leverage this emerging data set to inform the optimal study design for Phase 2 trials in ulcerative colitis and beyond.” In the Phase 1 SAD trial, MORF-057 was well tolerated in all 5 cohorts receiving MORF-057 in single doses ranging from 25 mg to 400 mg with no serious adverse events (SAEs) and no significant lab abnormalities in any subject. Morphic expects to present the full data set from the MORF-057 Phase 1 clinical trial at an appropriate medical meeting in mid-2021. finance.yahoo.com Meanwhile, the company's long-standing partnership with pharma giant AbbVie is moving forward. Under the collaboration agreement between these two entities, which started more than two years ago, AbbVie initially paid $100 million up front to Morphic to acquire exclusive license options for some of Morphic's candidates. Morphic Holding would be responsible for conducting research and development for these products up to the completion of investigational new drug enabling studies. AbbVie would then be able to exercise its license option for a fee to take up the development of these programs. Today, Morphic Holding announced that AbbVie paid a $20 million fee to assume the responsibility to develop and commercialize a couple of Morphic's pipeline candidates. Lastly, Morphic has a partnership with Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), which focuses on developing integrin therapeutics for conditions for which there are few adequate therapy options. Morphic announced that it has expanded this partnership with the pharma company. For a drugmaker with no products on the market, lucrative deals with well-established pharmaceutical companies are important. Morphic Holding will be able to use the funds it received from AbbVie to fund the clinical development of some of its other candidates, while its partnership with Janssen could bear fruit in the form of promising clinical compounds. These factors explain why investors are bidding up shares of Morphic Holding today. www.fool.com by AlenCiken442
MORF in an uptrendI am buying it at 31-32 if it finds the support within next 1-2 weeks. If not - alternatively will buy at 22-26 level. Take-profit - 44. Longby financialSnail88674Updated 223
Possible S/R flipThis might even count as a nice S/R flip. In this case see you again at ATH :DLongby dobisa1
$MORFEntry price : 32.66 Fundamentals : - Sector: Medical - Biotech - EPS % Chg (Last Qtr): 157% - EPS % Chg (Previous Qtr): -68% - 3 Year EPS Growth Rate: 0% - EPS Est % Chg (Current Yr): 0% - Sales % Chg (Last Qtr): 354% - Sales % Chg (Previous Qtr): 38% - 3-Year Sales Growth Rate: 167% - Annual Pre -Tax Margin: -249.8%Longby paulopicaocapeloUpdated 112
MORF 16H: BUY/HOLD 40% gains BUY/HOLD(STOCKS)Why get subbed to to me on Tradingview? -TOP author on TradingView -15+ years experience in markets -Professional chart break downs -Supply/Demand Zones -TD9 counts / combo review -Key S/R levels -No junk on my charts -Frequent updates -Covering FX/crypto/US stocks -24/7 uptime so constant updates MORF 16H: BUY/HOLD 40% gains(NEW) 🔸 Summary and potential trade setup . MORF 16hour chart review and strategy . Biotech sector outperforming market . in 2020 due to corona hype . accumulation at the bottom now . TP bulls is open gap at 27 USD . overall setup looks good . BUY mild dips / market BUY . TP bulls is 27 USD +40% gains . XABCD setup, point D at 27 USD . which is 100% upside from here . setup for patient traders . DO NOT expect overnight gains . This is stock market . Not casino in Macau 🔸 Supply/Demand Zones . fresh supply at 27 USD 🔸 Why should I follow your setups? . Check track record it's all been posted . MNRA 200%+ gains, NVAX 300% gains, REG 60% . AMD 40% gains and a lot more in recent monthsLongby ProjectSyndicateUpdated 11113
HEY MORFIT'S PROBABLY THAT NASDAQ:MORF GO DOWN DUE TO A RESISTENCE AT PRICE 19.20 Shortby richbenninghton7